Indefinite Delivery Contract SPE2DR25D6035

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract (IDC) SPE2DR25D1002, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, is a single-award contract valued at $9,999,999,999 running through December 31, 2036. This IDC serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes,...
The Indefinite Delivery Contract (IDC) SPE2DR25D1116 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 IDC has an ultimate completion date of December 31, 2036 and serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The original...
The Indefinite Delivery Contract (IDC) SPE2DR25D2105 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, covers the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines,...
The Indefinite Delivery Contract (IDC) SPE2DR25D1041 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,999,999,999 IDC has a period of performance from August 1, 2025 to December 31, 2036, and supports DLA, the Department of Defense (DoD), the U.S. Coast Guard, and other government agencies by providing a comprehensive range of pharmaceutical products...
The Indefinite Delivery Contract (IDC) SPE2DR25D7910 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a period of performance through December 2026 and is intended to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, the U.S. Coast Guard, and...
The Indefinite Delivery Contract (IDC) SPE2DU25D5117 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $999,999,999 and runs through December 2036, serving as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a 30-month base period and three 30-month option periods, running through December 2036. The purpose of this IDC is to establish a Pharmaceutical Prime Vendor Global Program to provide worldwide pharmaceutical support, including...
The Indefinite Delivery Contract (IDC) SPE2DR25D2206 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 contract, running through December 2036, is part of the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, U.S. Coast...
This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a base period of 30 months and three 30-month option periods, running through December 2036. The purpose of this IDC is to establish Pharmaceutical Prime Vendor contracts to provide worldwide pharmaceutical support to various...
The Indefinite Delivery Contract (IDC) SPE2DR25D2208 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $999,999,999 contract has a performance period through December 2036 and serves as a vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC encompasses critical medical commodities including...

The Indefinite Delivery Contract (IDC) SPE2DR25D6035 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, is a single-award IDC with a period of performance through December 31, 2036.

The purpose of this IDC is to establish a Pharmaceutical Prime Vendor Global Program to provide worldwide pharmaceutical support, including brand-name, generic, and specialty medications, as well as related medical supplies, to the Department of Defense (DoD), United States Coast Guard, and other designated federal customers. The contract covers normal day-to-day operations, planned and unplanned contingencies, Prime Vendor Readiness, and War Readiness Materiel support to both CONUS and OCONUS locations. The solicitation for this IDC is expected to be issued in March 2024 as an unrestricted, fully competitive acquisition with the intent to make multiple regional awards to ensure resiliency and access to vital pharmaceuticals.

Generated 6/6/25, 9:55 AM